Development of microfluidic angiogenesis assay for drug testing and companion diagnostics

Armour Therapeutics Inc是一家位于安大略多伦多的生物制药公司，该公司开发了一种用于晚期前列腺癌（PCa）的候选药物，晚期前列腺癌是加拿大和发达国家男性中最常见的癌症类型。候选药物AT-001为患者提供了继续激素治疗的可能性，甚至超过了肿瘤对传统抗激素治疗不敏感的程度。虽然Armour Therapeutics在将AT-001引入临床方面取得了进展，但与AT-001对血管生长或血管生成的影响相关的关键问题仍未得到解答。此外，药物监管机构越来越倾向于开发补充诊断测试，称为伴随诊断测试。

Armour Therapeutics Inc. is a biopharmaceutical company based in Toronto, Ontario that has developed a candidate drug for advanced prostate cancer (PCa), the most common type of cancer among men in Canada and in the developed world. The candidate drug, AT-001, offers the potential for patients to continue hormone therapy even beyond the point where tumours become insensitive to traditional anti-hormone therapies. While Armour Therapeutics has made progress to bring AT-001 to the clinic, key questions related to the effects of AT-001 on blood vessel growth, or angiogenesis, remain unanswered. Furthermore, drug regulatory bodies are increasingly favouring the development of complementary diagnostic tests, termed companion diagnostic